Please use this identifier to cite or link to this item:
http://hdl.handle.net/10668/10878
Title: | Highly Efficient Neural Conversion of Human Pluripotent Stem Cells in Adherent and Animal-Free Conditions. |
Authors: | Lukovic, Dunja Diez Lloret, Andrea Stojkovic, Petra Rodríguez-Martínez, Daniel Perez Arago, Maria Amparo Rodriguez-Jimenez, Francisco Javier González-Rodríguez, Patricia López-Barneo, José Sykova, Eva Jendelova, Pavla Kostic, Jelena Moreno-Manzano, Victoria Stojkovic, Miodrag Bhattacharya, Shomi S Erceg, Slaven |
Keywords: | Cellular therapy;Clinical translation;Differentiation;Embryonic stem cells;Induced pluripotent stem cells;Neural differentiation;Pluripotent stem cells |
metadata.dc.subject.mesh: | Cell Differentiation Cell- and Tissue-Based Therapy Cells, Cultured Embryonic Stem Cells Humans Induced Pluripotent Stem Cells Pluripotent Stem Cells |
Issue Date: | 18-Feb-2017 |
Abstract: | Neural differentiation of human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs) can produce a valuable and robust source of human neural cell subtypes, holding great promise for the study of neurogenesis and development, and for treating neurological diseases. However, current hESCs and hiPSCs neural differentiation protocols require either animal factors or embryoid body formation, which decreases efficiency and yield, and strongly limits medical applications. Here we develop a simple, animal-free protocol for neural conversion of both hESCs and hiPSCs in adherent culture conditions. A simple medium formula including insulin induces the direct conversion of >98% of hESCs and hiPSCs into expandable, transplantable, and functional neural progenitors with neural rosette characteristics. Further differentiation of neural progenitors into dopaminergic and spinal motoneurons as well as astrocytes and oligodendrocytes indicates that these neural progenitors retain responsiveness to instructive cues revealing the robust applicability of the protocol in the treatment of different neurodegenerative diseases. The fact that this protocol includes animal-free medium and human extracellular matrix components avoiding embryoid bodies makes this protocol suitable for the use in clinic. Stem Cells Translational Medicine 2017;6:1217-1226. |
URI: | http://hdl.handle.net/10668/10878 |
metadata.dc.identifier.doi: | 10.1002/sctm.16-0371 |
ISSN: | 2157-6564 |
Appears in Collections: | Producción 2020 |
Files in This Item:
File | Size | Format | |
---|---|---|---|
PMC5442830.pdf | 776,82 kB | Adobe PDF | View/Open |
This item is protected by original copyright |
This item is licensed under a Creative Commons License